175 related articles for article (PubMed ID: 35211429)
1. SHMT2 Drives the Progression of Colorectal Cancer by Regulating UHRF1 Expression.
Cui X; Cui Y; Du T; Jiang X; Song C; Zhang S; Ma C; Liu Y; Ni Q; Gao Y; Wang G
Can J Gastroenterol Hepatol; 2022; 2022():3758697. PubMed ID: 35211429
[TBL] [Abstract][Full Text] [Related]
2. Cytoplasmic SHMT2 drives the progression and metastasis of colorectal cancer by inhibiting β-catenin degradation.
Liu C; Wang L; Liu X; Tan Y; Tao L; Xiao Y; Deng P; Wang H; Deng Q; Lin Y; Jie H; Zhang H; Zhang J; Peng Y; Zhang H; Zhou Z; Sun Q; Cen X; Zhao Y
Theranostics; 2021; 11(6):2966-2986. PubMed ID: 33456583
[No Abstract] [Full Text] [Related]
3. Increased Expression of Serine Hydroxymethyltransferase 2 (SHMT2) is a Negative Prognostic Marker in Patients with Hepatocellular Carcinoma and is Associated with Proliferation of HepG2 Cells.
Ji L; Tang Y; Pang X; Zhang Y
Med Sci Monit; 2019 Aug; 25():5823-5832. PubMed ID: 31379360
[TBL] [Abstract][Full Text] [Related]
4. Deacetylation of serine hydroxymethyl-transferase 2 by SIRT3 promotes colorectal carcinogenesis.
Wei Z; Song J; Wang G; Cui X; Zheng J; Tang Y; Chen X; Li J; Cui L; Liu CY; Yu W
Nat Commun; 2018 Oct; 9(1):4468. PubMed ID: 30367038
[TBL] [Abstract][Full Text] [Related]
5. UHRF1 promotes cell growth and metastasis through repression of p16(ink⁴a) in colorectal cancer.
Wang F; Yang YZ; Shi CZ; Zhang P; Moyer MP; Zhang HZ; Zou Y; Qin HL
Ann Surg Oncol; 2012 Aug; 19(8):2753-62. PubMed ID: 22219067
[TBL] [Abstract][Full Text] [Related]
6. Downregulating serine hydroxymethyltransferase 2 (SHMT2) suppresses tumorigenesis in human hepatocellular carcinoma.
Woo CC; Chen WC; Teo XQ; Radda GK; Lee PT
Oncotarget; 2016 Aug; 7(33):53005-53017. PubMed ID: 27391339
[TBL] [Abstract][Full Text] [Related]
7. The loss of SHMT2 mediates 5-fluorouracil chemoresistance in colorectal cancer by upregulating autophagy.
Chen J; Na R; Xiao C; Wang X; Wang Y; Yan D; Song G; Liu X; Chen J; Lu H; Chen C; Tang H; Zhuang G; Fan G; Peng Z
Oncogene; 2021 Jun; 40(23):3974-3988. PubMed ID: 33990700
[TBL] [Abstract][Full Text] [Related]
8. miR-615-5p prevents proliferation and migration through negatively regulating serine hydromethyltransferase 2 (SHMT2) in hepatocellular carcinoma.
Wu X; Deng L; Tang D; Ying G; Yao X; Liu F; Liang G
Tumour Biol; 2016 May; 37(5):6813-21. PubMed ID: 26662310
[TBL] [Abstract][Full Text] [Related]
9. Induction of serine hydroxymethyltransferase 2 promotes tumorigenesis and metastasis in neuroblastoma.
Clark RA; Qiao J; Jacobson JC; Chung DH
Oncotarget; 2022; 13():32-45. PubMed ID: 35018218
[TBL] [Abstract][Full Text] [Related]
10.
Hu B; Xian Z; Zou Q; Zhang D; Su D; Yao J; Ren D
Cancer Biother Radiopharm; 2021 Feb; 36(1):45-57. PubMed ID: 32379550
[No Abstract] [Full Text] [Related]
11. High expression of SHMT2 is correlated with tumor progression and predicts poor prognosis in gastrointestinal tumors.
Liu Y; Yin C; Deng MM; Wang Q; He XQ; Li MT; Li CP; Wu H
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(21):9379-9392. PubMed ID: 31773687
[TBL] [Abstract][Full Text] [Related]
12. High Expression of Serine Hydroxymethyltransferase 2 Indicates Poor Prognosis of Gastric Cancer Patients.
Shi H; Fang X; Li Y; Zhang Y
Med Sci Monit; 2019 Oct; 25():7430-7438. PubMed ID: 31581160
[TBL] [Abstract][Full Text] [Related]
13. SHMT2 promotes the tumorigenesis of renal cell carcinoma by regulating the m6A modification of PPAT.
Huo FC; Xie M; Zhu ZM; Zheng JN; Pei DS
Genomics; 2022 Jul; 114(4):110424. PubMed ID: 35798250
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of SHMT2 promotes the prostate cancer proliferation and metastasis by inducing epithelial-mesenchymal transition.
Chen L; Liu H; Ji Y; Ma Z; Shen K; Shangguan X; Qian H; Zhao Y; Pan CW; Xue W
Exp Cell Res; 2022 Jun; 415(2):113138. PubMed ID: 35398308
[TBL] [Abstract][Full Text] [Related]
15. SRSF9 promotes colorectal cancer progression via stabilizing DSN1 mRNA in an m6A-related manner.
Wang X; Lu X; Wang P; Chen Q; Xiong L; Tang M; Hong C; Lin X; Shi K; Liang L; Lin J
J Transl Med; 2022 May; 20(1):198. PubMed ID: 35509101
[TBL] [Abstract][Full Text] [Related]
16. Cancer proteome and metabolite changes linked to SHMT2.
Tong J; Krieger JR; Taylor P; Bagshaw R; Kang J; Jeedigunta S; Wybenga-Groot LE; Zhang W; Badr H; Mirhadi S; Pham NA; Coyaud É; Yu M; Li M; Cabanero M; Raught B; Maynes JT; Hawkins C; Tsao MS; Moran MF
PLoS One; 2020; 15(9):e0237981. PubMed ID: 32903271
[TBL] [Abstract][Full Text] [Related]
17. SHMT2 Desuccinylation by SIRT5 Drives Cancer Cell Proliferation.
Yang X; Wang Z; Li X; Liu B; Liu M; Liu L; Chen S; Ren M; Wang Y; Yu M; Wang B; Zou J; Zhu WG; Yin Y; Gu W; Luo J
Cancer Res; 2018 Jan; 78(2):372-386. PubMed ID: 29180469
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance and biological role of KLF17 as a tumour suppressor in colorectal cancer.
Jiang X; Shen TY; Lu H; Shi C; Liu Z; Qin H; Wang F
Oncol Rep; 2019 Nov; 42(5):2117-2129. PubMed ID: 31545467
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and therapeutic value of mitochondrial serine hydroxyl-methyltransferase 2 as a breast cancer biomarker.
Zhang L; Chen Z; Xue D; Zhang Q; Liu X; Luh F; Hong L; Zhang H; Pan F; Liu Y; Chu P; Zheng S; Lou G; Yen Y
Oncol Rep; 2016 Nov; 36(5):2489-2500. PubMed ID: 27666119
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial serine hydroxymethyltransferase 2 is a potential diagnostic and prognostic biomarker for human glioma.
Wang B; Wang W; Zhu Z; Zhang X; Tang F; Wang D; Liu X; Yan X; Zhuang H
Clin Neurol Neurosurg; 2017 Mar; 154():28-33. PubMed ID: 28107674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
